Document Classification

Section Type: RESULTS

Text: There was no significant difference in the proportion of women with an LVEF less than 50 % at 5 to 8 (cyclophosphamide, doxorubicin, and fluorouracil [CAF] v cyclophosphamide, methotrexate, and fluorouracil [CMF] : 5 % v 7 % ; P =. 68) or 10 to 13 years (CAF v CMF : 3 % v 0 % ; P =. 16) ; however, in an exploratory analysis, the mean LVEF in the doxorubicin group was statistically significantly lower in the 5 - to 8-year sample (64. 8 % v 61. 4 % ; P =. 01) but not in the 10 - to 13-year sample.